lisocabtagene maraleucel CAR-T
Selected indexed studies
- CAR T-cell therapy for B-cell lymphoma. (Curr Probl Cancer, 2022) [PMID:35012754]
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. (Lancet, 2020) [PMID:32888407]
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. (Lancet, 2022) [PMID:35717989]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- CAR T-cell therapy for B-cell lymphoma. (2022) pubmed
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (2022) pubmed
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. (2020) pubmed
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. (2022) pubmed
- Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. (2024) pubmed
- CAR T-Cells. (2020) pubmed
- Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. (2022) pubmed
- Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma. (2025) pubmed
- Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review. (2023) pubmed
- Lisocabtagene Maraleucel. (2006) pubmed